Trending

rheumatoid arthriitis

AbbVie prices Rinvoq close to Humira after arthritis approval

AbbVie prices Rinvoq close to Humira after arthritis approval

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price

X

AbbVie prices Rinvoq close to Humira after arthritis approval

https://pharmaphorum.com/news/abbvie-prices-upadacitinib-close-to-humira-after-arthritis-approval/

Mycenax’s Actemra biosimilar edges closer to approval

Mycenax’s Actemra biosimilar edges closer to approval

Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase

X

Mycenax’s Actemra biosimilar edges closer to approval

https://pharmaphorum.com/news/mycenaxs-actemra-biosimilar-edges-closer-to-approval/

RA pill setback spoils Lilly’s growth story

RA pill setback spoils Lilly’s growth story

Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of

X

RA pill setback spoils Lilly’s growth story

https://pharmaphorum.com/news/ra-pill-setback-spoils-lillys-growth-story/

AbbVie looks beyond Humira as RA pill meets phase 3 targets

AbbVie looks beyond Humira as RA pill meets phase 3 targets

Upadacitinib hopes drug will reduce reliance on Humira.

X

AbbVie looks beyond Humira as RA pill meets phase 3 targets

https://pharmaphorum.com/news/abbvie-looks-beyond-humira-ra-pill-meets-phase-3-targets/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com